More than 150 techies packed the house at a Claude Code meetup event in Seattle on Thursday evening, eager to trade use cases ...

Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

The new global collaboration platform brings improvements in efficiency, making borderless cosmetics development ...

Discover the 10 key steps in developing new financial products, from concept to market launch, to understand their journey to ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

Program Updates and Anticipated 2026 Milestones: TN-201 -- Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM) ...

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

This new prototype aims to help filmmakers build audience during production, not after, and it's seeking testers.

Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing ...

SAN DIEGO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader ...